MedTrace Logo

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

NCT03739606 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-12-17

No results posted yet for this study

Summary

This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as flotetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Acute Biphenotypic Leukemia
  • Acute Leukemia
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Hairy Cell Leukemia
  • Interleukin-3 Receptor Subunit Alpha Positive
  • Recurrent Acute Lymphoblastic Leukemia
  • Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Recurrent Hematologic Malignancy
  • Recurrent Hodgkin Lymphoma
  • Refractory Acute Lymphoblastic Leukemia
  • Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Refractory Hematologic Malignancy
  • Refractory Hodgkin Lymphoma
  • Systemic Mastocytosis

Interventions

BIOLOGICAL

Anti-CD123/CD3 Monoclonal Antibody MGD006

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Ibrahim Aldoss, MD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2020-10-20
Completion
2020-10-20
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03739606 on ClinicalTrials.gov